Abstract:
Sexual disorders are the common side effects of SSRI group of
antidepressants, although, recently SSRIs have emerged as an effective new
treatment modality for premature ejaculation in a dose of 40 mg/day. Some
evidences suggest that SSRIs can cause untoward sexual experiences such as
changes in sexual desire, sexual performance and sexual satisfaction. Reliable
estimates of the incidence and severity of untoward experiences are difficult to
obtain, however, in part because patients and physicians may be reluctant to
discuss them. Accordingly, estimates of the incidence of untoward sexual
experience and performance, cited in product labeling, are likely to
underestimate their actual incidence. In patients eurolled in U.S. major
depressive disorder, OCD and bulimia nervosa placebo-controlled clinical
trials, decreased libido was the only sexual side effect. There are no adequate
and well controlled studies examining sexual dysfunction with Fluoxetine
treatment. There have been spontaneous reports in women taking Fluoxetine of
orgasmic dysfunction, including anorgasmia. Because Fluoxetine is prototype
of SSRIs and most commonly used in different doses for different psychiatric
disorders such as for depression and phobias in low doses i.e.10 and 20 mg/day
but in high doses up to 80 mg/day for OCD and bulimia nervosa. For almost all
the psychiatric illnesses the SSRIs are used for long duration. Therefore, the
86
objective of the present study was to deduce the comparative safety of
Fluoxetine in acute and subacute therapy and to study the histological changes
in various cells of urogenital system of albino rats after intraperitoneal injection
of Fluoxetine in different doses. 72 albino rats viere taken for the study which
was conducted in 3 phases of 2, 4 and 12 weeks duration. Each phase consisted
of 24 rats. These 24 rats were further subdivided into 4 groups of 6 rats each (3
males and 3 females). Group 1 (Control) received intraperitoneal injection of
vehicle (normal saline). Group 2, Group 3 and Group 4 received 10 mg, 20 mg
and 40 mg/kg of body weight/day intraperitoneal injection of Fluoxetine
respectively.
